The local healthcare industry is the backbone of healthcare services, serving as a solid support structure for the country’s requirements. Green Pharmacy is a notion that became the idea of the Indonesian pharmaceutical business by exploiting natural biodiversity in the form of Indonesian Indigenous Modern Medicines items manufactured using modern technology yet have a low environmental impact.
On Tuesday, March 8, 2022, this idea was proposed in the T20 discussion thread. T20 becomes a venue for global think tanks and professionals to offer a complete analysis of the current G20 debates and generate ideas to assist the G20 in establishing tangible and sustainable policy. The T20’s conclusions were offered to G20 working groups, ministers, and state leaders as an alternative strategy, not as a recommendation. Meanwhile, the Group of 20 (G20) is an international cooperation forum comprising 19 nations and the European Union’s economic region. This year, Indonesia will become the G20 Presidency as the host of the G20 event, commencing from December 1, 2021, until the G20 Summit in November 2022.
During the discussion, a pharmaceutical industry proposal was proposed to utilize Indonesian natural raw materials, which is a solution for the state to minimize the dangers of the pharmaceutical supply chain. Due to the COVID-19 epidemic, nations importing raw medication materials restricted import taps, creating barriers in the medicine supply chain.
“The local health industry is the backbone of health care service, providing a solid support structure for the country’s requirements. This service includes vendors, suppliers, and healthcare providers in the industrial supply chain. With the help of local business, Indonesia’s G20 presidency is leading collaborative efforts to enable more appropriate, sufficient, and cheap access to vaccinations, diagnostics, PPE, and COVID-19 treatment,” stated Health Minister Budi Gunadi Sadikin at the Think Tank discussion event, T20 with the subject The Future of Indonesian Healthcare.
According to Budi, health product resources and capability growth are critical to strengthening the global health architecture.
Kunta Wibawa Dasa Nugraha, Secretary-General of the Ministry of Health of the Republic of Indonesia, stated that the Indonesian government had made several steps to grow global manufacturing and knowledge centers. These include increasing the availability of COVID-19 vaccines, treatments, and diagnostics to manufacturing facilities in low- and middle-income countries and boosting the worldwide network of specialists in virology, immunology, epidemiology, and other public health-related domains.
The local pharmaceutical sector in Indonesia has taken many initiatives and attempts to promote health resilience and independence, one of which is the idea of Green Pharmacy. Dr. Raymond Tjandrawinata, Executive Director Dexa Laboratories of Biomolecular Sciences PT Dexa Medica, proposed the notion of Green Pharmacy as a plan that should be pursued.
“Green Pharmacy may insulate a country from supply issues, environmental issues, and healthcare access issues.” Only by realizing and implementing this plan would the country be able to achieve independence, have a stronger environmental and ecological system, enhance farmer welfare, and boost independence in terms of active raw materials (API) originating in our own country,” he stated.
Green Sector has been widely employed in the public industry in Indonesia, but not in the pharmaceutical sector. “We are advocating for the formation of a collaboration to enable Green Pharmacy in the future.” While we wait for more Green Pharmacy, the government should pay attention to this issue since the worldwide supply-demand chain for our API is extremely excellent. “We must support this,” Dr. Raymond stated.
Like Indonesian Indigenous Modern Medicine, Green Pharmacy does not imply that it is processed traditionally, but rather modern and technologically sophisticated. Government policies should stimulate the growth of Green Pharmacy and the placement of its goods in healthcare institutions such as public hospitals.
“We need to collect data and conduct clinical studies to ensure Green Pharmacy complies with worldwide standards and medication classifications. Green Pharmacy should eventually account for most pharmaceuticals on a country’s formulary. This purpose is our ambition and achievable if the government and private sector work together to make it a reality. Therefore Green Pharmacy is a brilliant option for many nations,” Dr. Raymond explained.
Prof. Hasbullah Thabrany, Chief of T20 of the G20 Global Health Sector, stated that the government and stakeholders must promote the growth of the national health sector. Healthcare funding in emerging countries is lower than in developed countries. Over the last two decades, a rising number of emerging nations, such as South Korea, Indonesia, and Saudi Arabia, have caught up with them by boosting their healthcare spending.
“Perhaps Green Pharmacy is one of the attempts in this regard. Creating new pharmaceuticals from plants will aid in the reduction of climate change and the creation of a greener future. Tropical nations produce a large number of phytopharmaceuticals. India has a long history of employing herbal therapy to assist people all over the world,” Prof. Hasbullah added.